Posts Tagged ‘GE Healthcare’

Insights from CGTW16 – Part 2: scale-up challenges and closed systems

Author: Guest, 11/23/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Right Turn: Regenerative medicine debuts on The Late Show

Author: Stacey Johnson, 01/22/16

Does it seem like regenerative medicine is having its moment in the sun? Last week, the news that GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies, with $20 million coming from the Government of Canada and a matching $20 million coming from GE…Read more

Right Turn: New $40M centre will solve cell therapy manufacturing challenges

Author: Stacey Johnson, 01/15/16

It was huge news in Canada on Wednesday (January 13) when the Centre for Commercialization of Regenerative Medicine (CCRM) and GE Healthcare announced their partnership in the development of a new centre for advanced therapeutic cell technologies. GE Healthcare is providing CAD $20 million that the Federal Economic Development Agency for Southern Ontario (FedDev Ontario)…Read more

Highlights from the 2015 “Business of Regenerative Medicine” course

Author: Guest, 08/27/15

. Nadia Houri is a Business Development Analyst with the Centre for Commercialization of Regenerative Medicine (CCRM).   Last month, I had the pleasure of attending The Business of Regenerative Medicine: Cells at Work course, hosted by Georgia Tech, in Atlanta. With two and a half very full days of lectures and networking opportunities, cells…Read more

Cell Therapy Commercialization: A View from GE Healthcare on Immunotherapy

Author: Mark Curtis, 11/04/14

. Those following the regenerative medicine (RM) industry are likely in-tune with a rapidly evolving market, on the periphery, that is shaping up to provide a very attractive value proposition to patients, industry, and investors alike. The health care industry is undergoing a paradigm shift: Big Pharma has historically spread its efforts across palliative and substitutive…Read more

Right Turn: Lights, camera, action!

Author: Stacey Johnson, 11/15/13

. Sometimes too much choice can be a bad thing. It paralyzes you. I was flummoxed by the many options available to me in selecting what to feature on Right Turn this week. Then it struck me: I have the perfect item right under my nose (so to speak). CCRM just launched a Regenerative Medicine…Read more

iPS cells can help speed traditional drug development

Author: Paul Krzyzanowski, 05/11/10

Imagine that you’ve just discovered a novel drug that potentially solves a medical problem, one that accelerates wound healing in skin or can reduce the size of cancerous tumors. You can show the effects beautifully in your model tissue culture system and mice obviously respond to the treatment. You decide to call your technology transfer…Read more